Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

Good morning. I know this week probably feels extra long as we approach Labor Day weekend, but we will get through it together.

The need-to-know this morning

• Alumis said its experimental treatment for lupus failed to achieve the efficacy goals of a mid-stage clinical trial. 

Trump strikes more drug pricing deals with biotechs

President Trump yesterday announced that his administration has made deals with nine new companies, joining the 17 that it previously struck agreements with.

Continue to STAT+ to read the full story…